Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Abstract Background Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we reported in one case that a new symptom, Prurigo Nodularis (PN), developed...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-07-01
|
| Col·lecció: | Allergy, Asthma & Clinical Immunology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13223-023-00811-5 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|